Harmony Biosciences vs Nasus Pharma
HRMY and NSRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HRMY and NSRX compare
Harmony Biosciences keeps more of each dollar of sales as profit, with a net margin of 18.1% compared with −0.47% at Nasus Pharma.
Harmony Biosciences scores higher on the StockData Score (18 against 6 for Nasus Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HRMY | NSRX |
|---|---|---|
| Size and price | ||
| Market cap | $2.0B | – |
| Share price | $33.76 | $2.87 |
| Change, 1 year | 0.66% | −62.2% |
| Change, 5 years | −12.9% | – |
| Beta (5Y) | 0.93 | 1.33 |
| Employees | 293 | – |
| StockData Score | ||
| Total score | 18 (better) | 6 |
| Valuation score | 6 (better) | 0 |
| Growth score | 2 (better) | 0 |
| Performance score | 4 (better) | 1 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 11.1× | – |
| P/S | 2.0× | – |
| P/B | 1.8× | – |
| EV/EBITDA | 6.1× | – |
| Fair value | $56.70 | – |
| Margin of safety | 40.5% | – |
| Growth | ||
| Revenue growth (TTM) | 19.8% | – |
| Revenue growth, 5Y average | 40.3% | – |
| Net income growth (TTM) | −3.8% | – |
| EPS growth (TTM) | −4.7% | – |
| Profitability | ||
| Gross margin | 74.0% | – |
| Operating margin | 22.2% (better) | −0.40% |
| Net margin | 18.1% (better) | −0.47% |
| FCF margin | – | −0.40% |
| Return on equity | 18.7% (better) | −175% |
| Return on invested capital | 43.1% | – |
| Financial health | ||
| Debt / equity | 0.14 (better) | 0.00 |
| Net debt / EBITDA | −2.84 | – |
| Interest coverage | 17.0× | – |
| Current ratio | 3.44 | 8.77 (better) |
| Altman Z-score | 4.90 | – |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 93.0% | 23.9% |
| Held by insiders | 12.1% | 59.3% |
| Insider net buying, 12 months | −$5.8M | $61.8K (better) |
| Short interest, % of float | 13.0% | 1.9% |
Go deeper
- HRMY stock overview
- HRMY income statement
- HRMY valuation and score
- NSRX stock overview
- NSRX income statement
- NSRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.